June 15, 2018 Product Launch

New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan

Basel, 15 June 2018 New long-term data confirm Roche’s Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan After a follow-up time of nearly five years the CLL11 study shows a 51% reduction in the risk of disease progression or death with Gazyva/Gazyvaro compared to MabThera/Rituxan The final analysis reports a... Read more

June 14, 2018 Licensing, IP, and Legal Product Launch

Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis

Basel, 14 June 2018 Roche announces new OCREVUS (ocrelizumab) data on long-term disability benefits in primary progressive multiple sclerosis and initiation of two global studies in progressive multiple sclerosis OCREVUS may delay the need for a wheelchair by seven years for people with primary progressive multiple sclerosis (PPMS) Longer-term efficacy and safety data are consistent... Read more

June 13, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

June 13, 2018 Acad, Gov/Utilities

FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery

Basel, 13 June 2018 FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery Avastin is now approved for ten distinct uses across six different types of cancer in the United States Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug... Read more

June 11, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more

June 11, 2018 Acad, Gov/Utilities Bio/Pharma/CRO

Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia

Basel, 11 June 2018 Roche announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukaemia Approval based on phase III MURANO study showing Venclexta plus Rituxan reduced risk of disease progression or death by 81% compared to bendamustine plus Rituxan Roche (SIX: RO, ROG; OTCQX: RHHBY), announced today that the... Read more

June 5, 2018 Acad, Gov/Utilities

FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors

Basel, 05 June 2018 FDA grants Priority Review to Roche’s Hemlibra for people with haemophilia A without factor VIII inhibitors Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Hemlibra® (emicizumab-kxwh) for adults and... Read more

June 3, 2018 Clinical Research/Diagn. PR/Corporate Product Launch

Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting

Basel, 03 June 2018 Roche presents new data across a range of blood cancers at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting Further data demonstrate polatuzumab vedotin’s clinical efficacy across a range of diffuse large B-cell lymphoma subgroups Additional results from the randomised phase III MURANO study support fixed-duration Venclexta/Venclyxto plus MabThera/Rituxan... Read more

June 2, 2018 Bio/Pharma/CRO PR/Corporate

Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer

Basel, 02 June 2018 Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer Data will be featured in the ASCO press programme on Saturday 2 June and presented at ASCO on Monday 4 June Roche (SIX:... Read more